Welcome to LookChem.com Sign In|Join Free

CAS

  • or

146-77-0

Post Buying Request

146-77-0 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

146-77-0 Usage

Uses

Different sources of media describe the Uses of 146-77-0 differently. You can refer to the following data:
1. 2-Chloroadenosine is an adenosine analogue that is not hydrolyzed by adenosine deaminase. 2-Chloroadenosine increases the rate of dopa production in intact pheochromocytoma cells, it increases the content of cAMP in the cells, and it causes a stable activation of tyrosine hydroxylase, as measured in vitro. The action of 2-Chloroadenosine is not dependent upon extracellular Ca2+. In other experiments, we have found that 2-chloroadenosine increases the activity of adenylate cyclase in membrane fractions prepared from the pheochromocytoma. These data provide support for the hypothesis that 2-Chloroadenosine causes a cAMP-mediated phosphorylation of tyrosine hydroxylase in pheochromocytoma cells. Chromaffin cells and adrenergic neurons store and release adenine nuc1eotides together with catecho1amines. The adenosine formed by the hydrolysis of these nucleotides may be involved in the. physiological regulation of adenylate cyclase activity and of tyrosine hydroxylase activity. To date , however, we have no evidence for such a role of adenosine in normal chromaffin cells or in adrenergic neurons.
2. A selective A1-adenosine receptor agonist. Induces apoptosis
3. Selective A1 adenosine receptor agonist. Since 2-chloroadenosine is not deaminated by adenosine deaminase and is less rapidly taken up by the brain than adenosine, 2-chloroadenosine led to more marked increase in CBF than adenosine.
4. 2-Chloroadenosine is used as a selective A1-adenosine receptor agonist, and also Induces apoptosis.

Chemical Properties

White to Off-White Crystalline Sold

Definition

A metabolically stable analog of adenosine which acts as an adenosine receptor agonist. The compound has a potent effect on the peripheral and central nervous system.

Biological Activity

Metabolically stable analog of adenosine that behaves as an adenosine receptor agonist (K i values are 300, 80 and 1900 nM for A 1 , A 2A and A 3 receptors respectively). Anticonvulsive in vivo .

Biochem/physiol Actions

2-Chloroadenosine is an analog of adenosine. It is an adenosine A1 receptor agonist. It might possess anti-oxidant property.

Pharmacology

2-chloroadenosine (2-CAdo) is an adenosine deaminase-resistant analogue of adenosine, widely used as an adenosine receptor agonist. This compound has been shown to induce apoptosis in several cell types either via activation of adenosine receptors or via intracellular metabolism. However, the molecular mechanisms of 2-CAdo-induced apoptosis are unclear. Here, we analyzed the effects of 2-CAdo in the leukemia cell line EHEB. 2-CAdo was found to induce apoptosis in EHEB cells, as shown by caspase-3 activation, DNA fragmentation, poly(ADP-ribose) polymerase (PARP) cleavage and phosphatidylserine exposure. Cytotoxicity of 2-CAdo was completely suppressed by 5-iodotubercidin, an adenosine kinase inhibitor, indicating that apoptosis induced by 2-CAdo was the result of its intracellular metabolism. Accordingly, we found that 2-CAdo was efficiently converted into 2-chloroATP. In parallel, a decrease of intracellular ATP concentration as well as a general inhibition of macromolecular synthesis, involving DNA, RNA and protein synthesis, was observed. Moreover, 2-CAdo induced cytochrome c release into the cytosol, indicating activation of the intrinsic pathway of apoptosis. This was found associated with a decline in Mcl-1 protein level and p53-independent. Inhibition of AMP deaminase by coformycin markedly prevented ATP depletion, and also significantly reduced 2-CAdo cytotoxicity and caspase-3 activation. In conclusion, our data show that intracellular metabolism of 2-CAdo can lead to activation of the intrinsic pathway of apoptosis and that ATP depletion, in addition to the accumulation of the triphosphate analogue, contributes to 2-CAdo-induced apoptosis.

Purification Methods

Purify 2-chloroadenosine by recrystallisation from H2O (~1% in cold), and it has max at 264 nm (pH 1 and 7) and 265 nm (pH 13) in H2O. [Brown & Weliky J Org Chem 23 125 1958, Schaeffer & Thomas J Am Chem Soc 80 3738 1958, IR: Davoll & Lewy J Am Chem Soc 74 1563 1952, Beilstein 26 III/IV 3725.]

Check Digit Verification of cas no

The CAS Registry Mumber 146-77-0 includes 6 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 3 digits, 1,4 and 6 respectively; the second part has 2 digits, 7 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 146-77:
(5*1)+(4*4)+(3*6)+(2*7)+(1*7)=60
60 % 10 = 0
So 146-77-0 is a valid CAS Registry Number.
InChI:InChI=1/C10H14N6O4/c11-7-4-8(15-10(12)14-7)16(2-13-4)9-6(19)5(18)3(1-17)20-9/h2-3,5-6,9,17-19H,1H2,(H4,11,12,14,15)/t3-,5+,6?,9-/m1/s1

146-77-0 Well-known Company Product Price

  • Brand
  • (Code)Product description
  • CAS number
  • Packaging
  • Price
  • Detail
  • TCI America

  • (C2192)  2-Chloroadenosine Hydrate  >98.0%(HPLC)(T)

  • 146-77-0

  • 100mg

  • 590.00CNY

  • Detail
  • TCI America

  • (C2192)  2-Chloroadenosine Hydrate  >98.0%(HPLC)(T)

  • 146-77-0

  • 1g

  • 1,990.00CNY

  • Detail
  • Sigma

  • (C5134)  2-Chloroadenosine  

  • 146-77-0

  • C5134-10MG

  • 933.66CNY

  • Detail
  • Sigma

  • (C5134)  2-Chloroadenosine  

  • 146-77-0

  • C5134-50MG

  • 3,221.01CNY

  • Detail
  • Sigma

  • (C5134)  2-Chloroadenosine  

  • 146-77-0

  • C5134-250MG

  • 11,109.15CNY

  • Detail
  • Sigma

  • (C5134)  2-Chloroadenosine  

  • 146-77-0

  • C5134-1G

  • 34,304.40CNY

  • Detail

146-77-0Synthetic route

2',3',5'-tri-O-acetyl-2-chloroadenosine
79999-39-6, 24638-99-1

2',3',5'-tri-O-acetyl-2-chloroadenosine

2-Chloroadenosine
146-77-0

2-Chloroadenosine

Conditions
ConditionsYield
With methanol; sodium methylate for 1h; Reflux;96%
2-chloroadenine
1839-18-5

2-chloroadenine

uridine
58-96-8

uridine

2-Chloroadenosine
146-77-0

2-Chloroadenosine

Conditions
ConditionsYield
With hydrogenchloride; potassium dihydrogenphosphate; potassium hydroxide In water; dimethyl sulfoxide at 58 - 61℃; for 4h; pH=7.1-7.2; Enzymatic reaction;85%
With potassium phosphate; Geobacillus thermoglucosidasius purine nucleoside phosphorylase; Thermus thermophilus pyrimidine nucleoside phosphorylase In water at 70℃; for 1h; pH=7; Enzymatic reaction;
With dipotassium hydrogenphosphate; purine nucleoside phosphorylase; pyrimidine nucleoside phosphorylase; glycine In aq. buffer at 60℃; pH=9; Equilibrium constant; Enzymatic reaction;
(2R,3R,4R,5R)-4-(acetyloxy)-2-[(acetyloxy)methyl]-5-(2,6-dichloro-9H-purin-9-yl)tetrahydro-3-furanyl acetate
3056-18-6

(2R,3R,4R,5R)-4-(acetyloxy)-2-[(acetyloxy)methyl]-5-(2,6-dichloro-9H-purin-9-yl)tetrahydro-3-furanyl acetate

2-Chloroadenosine
146-77-0

2-Chloroadenosine

Conditions
ConditionsYield
With ethanol; ammonia at 20℃;75%
With ammonia In ethanol at 100℃; for 24h;73%
With ammonium hydroxide In tetrahydrofuran for 72h; Ambient temperature; Yield given;
2-chloro-2′,3′,5′-tri-O-(t-butyldimethylsilyl)adenosine
195727-26-5

2-chloro-2′,3′,5′-tri-O-(t-butyldimethylsilyl)adenosine

2-Chloroadenosine
146-77-0

2-Chloroadenosine

Conditions
ConditionsYield
With potassium fluoride In methanol at 80℃; for 24h;74%
2-chloroadenine
1839-18-5

2-chloroadenine

2-Chloroadenosine
146-77-0

2-Chloroadenosine

Conditions
ConditionsYield
With hydrogenchloride; potassium dihydrogenphosphate; potassium hydroxide In water; dimethyl sulfoxide at 58 - 61℃; for 4h; pH=7.1-7.2; Enzymatic reaction;70%
With Trypanosoma brucei purine nucleoside 2'-deoxyribosyltransferase, Y5F mutant In aq. phosphate buffer at 50℃; for 0.5h; pH=6.5; Enzymatic reaction;
6-amino-2-chloro-9-(2',3',5'-tri-O-benzoyl-β-D-ribofuranosyl)-9H-purine
1055168-98-3

6-amino-2-chloro-9-(2',3',5'-tri-O-benzoyl-β-D-ribofuranosyl)-9H-purine

2-Chloroadenosine
146-77-0

2-Chloroadenosine

Conditions
ConditionsYield
With sodium methylate In methanol at 20℃; for 7h;67%
2-chloro-6-methoxy-purine riboside
15465-92-6

2-chloro-6-methoxy-purine riboside

2-Chloroadenosine
146-77-0

2-Chloroadenosine

Conditions
ConditionsYield
With methanol; ammonia
2,8-dichloro-adenosine
75802-60-7

2,8-dichloro-adenosine

2-Chloroadenosine
146-77-0

2-Chloroadenosine

Conditions
ConditionsYield
With sodium hydroxide; Pd-BaSO4 Hydrogenation;
(1R)-tri-O-benzoyl-1-<2,6-dichloro-purin-9-yl>-1,4-anhydro-ribitol

(1R)-tri-O-benzoyl-1-<2,6-dichloro-purin-9-yl>-1,4-anhydro-ribitol

2-Chloroadenosine
146-77-0

2-Chloroadenosine

Conditions
ConditionsYield
With methanol; ammonia
2,3,5-tri-O-acetyl-α-D-ribofuranosyl chloride
105499-44-3

2,3,5-tri-O-acetyl-α-D-ribofuranosyl chloride

6-amino-2chloro-purin-9-ylmercury(1+) chloride

6-amino-2chloro-purin-9-ylmercury(1+) chloride

2-Chloroadenosine
146-77-0

2-Chloroadenosine

Conditions
ConditionsYield
With xylene und Behandeln des Reaktionsprodukts mit methanol.NH3;
(2R,3R,4R,5R)-2-((benzoyloxy)methyl)-5-(2,6-dichloro-9H-purin-9-yl)tetrahydrofuran-3,4-diyl dibenzoate
15373-23-6

(2R,3R,4R,5R)-2-((benzoyloxy)methyl)-5-(2,6-dichloro-9H-purin-9-yl)tetrahydrofuran-3,4-diyl dibenzoate

2-Chloroadenosine
146-77-0

2-Chloroadenosine

Conditions
ConditionsYield
With ammonia In methanol at 20℃;
With ammonia In methanol at 100℃; for 24h; Autoclave;14 g
With ammonia In methanol at 100℃; for 24h; Autoclave;14 g
1-[9-(2,3,5-tri-O-acetyl-β-D-ribofuranosyl)-2-chloropurin-6-yl]-3-benzyl-2-propylimidazolium iodide

1-[9-(2,3,5-tri-O-acetyl-β-D-ribofuranosyl)-2-chloropurin-6-yl]-3-benzyl-2-propylimidazolium iodide

2-Chloroadenosine
146-77-0

2-Chloroadenosine

Conditions
ConditionsYield
With ammonia In methanol at 60℃; for 11h;
9-(2,3,5-tri-O-acetyl-β-D-ribofuranosyl)-2-chloro-6-(2-propylimidazol-1-yl)purine
891497-89-5

9-(2,3,5-tri-O-acetyl-β-D-ribofuranosyl)-2-chloro-6-(2-propylimidazol-1-yl)purine

2-Chloroadenosine
146-77-0

2-Chloroadenosine

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: NaI / acetonitrile / 1.5 h / 60 °C
2: NH3 / methanol / 11 h / 60 °C
View Scheme
1-O-acetyl-2,3,5-tri-O-benzoyl-β-D-ribofuranose
6974-32-9

1-O-acetyl-2,3,5-tri-O-benzoyl-β-D-ribofuranose

thioether-bound (4-hydroxypyrimidine-2-yl)-Merrifield resin

thioether-bound (4-hydroxypyrimidine-2-yl)-Merrifield resin

2-Chloroadenosine
146-77-0

2-Chloroadenosine

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: SnCl4 / acetonitrile / 20 °C
2: NH3 / methanol / 20 °C
View Scheme
2,6 dichloropurine
5451-40-1

2,6 dichloropurine

2-Chloroadenosine
146-77-0

2-Chloroadenosine

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: SnCl4 / acetonitrile / 20 °C
2: NH3 / methanol / 20 °C
View Scheme
Multi-step reaction with 3 steps
1: tin(IV) chloride / 0.25 h / 90 - 120 °C
2: ammonia / methanol / 24 h / 100 °C / Autoclave
3: 24 h / 20 °C
View Scheme
2-amino-6-chloro-9-(2,3,5-tri-O-acetyl-β-D-ribofuranosyl)purine
16321-99-6

2-amino-6-chloro-9-(2,3,5-tri-O-acetyl-β-D-ribofuranosyl)purine

2-Chloroadenosine
146-77-0

2-Chloroadenosine

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: Ph3CCl, K2CO3, isoamyl nitrite / CH2Cl2 / 0.5 h / Heating
2: conc. NH4OH / tetrahydrofuran / 72 h / Ambient temperature
View Scheme
Multi-step reaction with 2 steps
1: benzyltriethylammonium nitrite; acetyl chloride / dichloromethane / 1 h / 0 °C / Inert atmosphere; Cooling with ice
2: ammonia / ethanol / 72 h / 20 °C
View Scheme
Multi-step reaction with 2 steps
1: benzyltriethylammonium nitrite; acetyl chloride / dichloromethane / Inert atmosphere; Cooling with ice
2: ammonia; ethanol / 20 °C
View Scheme
2-Chloroadenosine
146-77-0

2-Chloroadenosine

Conditions
ConditionsYield
Multi-step reaction with 4 steps
1: pyridine / dimethylformamide / 4.5 h / 75 °C
2: 70.85 percent / Et4NCl, Me2NPh, POCl3 / acetonitrile / 0.17 h / Heating
3: Ph3CCl, K2CO3, isoamyl nitrite / CH2Cl2 / 0.5 h / Heating
4: conc. NH4OH / tetrahydrofuran / 72 h / Ambient temperature
View Scheme
Multi-step reaction with 4 steps
1: dmap; N,N-dimethyl-ethanamine / acetonitrile / 1 h / 20 °C
2: tetraethylammonium chloride; N,N-dimethyl-aniline; trichlorophosphate / 100 °C
3: benzyltriethylammonium nitrite; acetyl chloride / dichloromethane / 1 h / 0 °C / Inert atmosphere; Cooling with ice
4: ammonia / ethanol / 72 h / 20 °C
View Scheme
Multi-step reaction with 4 steps
1: N,N-dimethyl-ethanamine; dmap / acetonitrile
2: tetraethylammonium chloride; trichlorophosphate; N,N-dimethyl-aniline / Inert atmosphere
3: benzyltriethylammonium nitrite; acetyl chloride / dichloromethane / Inert atmosphere; Cooling with ice
4: ammonia; ethanol / 20 °C
View Scheme
2',3',5'-tri-O-acetyl-guanosine
6979-94-8

2',3',5'-tri-O-acetyl-guanosine

2-Chloroadenosine
146-77-0

2-Chloroadenosine

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: 70.85 percent / Et4NCl, Me2NPh, POCl3 / acetonitrile / 0.17 h / Heating
2: Ph3CCl, K2CO3, isoamyl nitrite / CH2Cl2 / 0.5 h / Heating
3: conc. NH4OH / tetrahydrofuran / 72 h / Ambient temperature
View Scheme
Multi-step reaction with 3 steps
1: tetraethylammonium chloride; N,N-dimethyl-aniline; trichlorophosphate / 100 °C
2: benzyltriethylammonium nitrite; acetyl chloride / dichloromethane / 1 h / 0 °C / Inert atmosphere; Cooling with ice
3: ammonia / ethanol / 72 h / 20 °C
View Scheme
Multi-step reaction with 3 steps
1: tetraethylammonium chloride; trichlorophosphate; N,N-dimethyl-aniline / Inert atmosphere
2: benzyltriethylammonium nitrite; acetyl chloride / dichloromethane / Inert atmosphere; Cooling with ice
3: ammonia; ethanol / 20 °C
View Scheme
ammonium hydroxide
1336-21-6

ammonium hydroxide

2,6-dichloro-9-(2,3,5-O-triacetyl-β-D-ribofuranosyl)-9H-purine

2,6-dichloro-9-(2,3,5-O-triacetyl-β-D-ribofuranosyl)-9H-purine

2-Chloroadenosine
146-77-0

2-Chloroadenosine

Conditions
ConditionsYield
In tetrahydrofuran
D-ribose
50-69-1

D-ribose

2-chloroadenine
1839-18-5

2-chloroadenine

2-Chloroadenosine
146-77-0

2-Chloroadenosine

Conditions
ConditionsYield
With potassium dihydrogenphosphate; recombinant E.coli phosphopentomutase; recombinant E.coli purine nucleoside phosphorylase; recombinant E.coli ribokinase; potassium chloride; ATP; manganese(ll) chloride In aq. buffer at 50℃; for 0.5h; pH=7.5; Enzymatic reaction;90 %Chromat.
O6-(benzotriazol-1-yl)-2-chloro-9-[2,3,5-tri-O-(t-butyldimethylsilyl)-β-D-ribofuranosyl]purine
1277176-33-6

O6-(benzotriazol-1-yl)-2-chloro-9-[2,3,5-tri-O-(t-butyldimethylsilyl)-β-D-ribofuranosyl]purine

2-Chloroadenosine
146-77-0

2-Chloroadenosine

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: ammonium hydroxide / 1.5 h / 20 °C
2: potassium fluoride / methanol / 24 h / 80 °C
View Scheme
O6-(benzotriazol-1H-yl)-2',3',5'-tri-O-(tert-butyldimethylsilyl)guanosine
1182847-52-4

O6-(benzotriazol-1H-yl)-2',3',5'-tri-O-(tert-butyldimethylsilyl)guanosine

2-Chloroadenosine
146-77-0

2-Chloroadenosine

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: tert.-butylnitrite; chloro-trimethyl-silane / dichloromethane / 1 h / 0 °C
2: ammonium hydroxide / 1.5 h / 20 °C
3: potassium fluoride / methanol / 24 h / 80 °C
View Scheme
2-chloroadenine
1839-18-5

2-chloroadenine

2-Chloroadenosine
146-77-0

2-Chloroadenosine

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: tin(IV) chloride / nitromethane / 3 h / 20 °C / Cooling with ice
2: sodium methylate; methanol / 1 h / Reflux
View Scheme
1-β-D-ribofuranosyl-1H-benzotriazole
65024-85-3

1-β-D-ribofuranosyl-1H-benzotriazole

2-Chloroadenosine
146-77-0

2-Chloroadenosine

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: tin(IV) chloride / nitromethane / 3 h / 20 °C / Cooling with ice
2: sodium methylate; methanol / 1 h / Reflux
View Scheme
2,6-dichloropurine riboside
13276-52-3

2,6-dichloropurine riboside

2-Chloroadenosine
146-77-0

2-Chloroadenosine

Conditions
ConditionsYield
With ammonia In methanol at 80℃; for 7h; High pressure;
at 20℃; for 24h;4.5 g
1,2,3,5-tetraacetylribose
13035-61-5

1,2,3,5-tetraacetylribose

2-Chloroadenosine
146-77-0

2-Chloroadenosine

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: tin(IV) chloride / 0.25 h / 90 - 120 °C
2: ammonia / methanol / 24 h / 100 °C / Autoclave
3: 24 h / 20 °C
View Scheme
C5H9O8P(2-)*2K(1+)

C5H9O8P(2-)*2K(1+)

2-chloroadenine
1839-18-5

2-chloroadenine

2-Chloroadenosine
146-77-0

2-Chloroadenosine

Conditions
ConditionsYield
With E-purine nucleoside phosphorylase-0002 In aq. buffer at 40℃; for 0.3h; pH=9; Equilibrium constant; Reagent/catalyst; Temperature; pH-value; Enzymatic reaction;
5-fluorouridine
316-46-1

5-fluorouridine

2-Chloroadenosine
146-77-0

2-Chloroadenosine

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: E-pyrimidine nucleoside phosphorylase-0002; potassium dihydrogenphosphate / aq. buffer / 0.2 h / 40 °C / pH 9 / Enzymatic reaction
2: E-purine nucleoside phosphorylase-0002 / aq. buffer / 0.3 h / 40 °C / pH 9 / Enzymatic reaction
View Scheme
2-Chloroadenosine
146-77-0

2-Chloroadenosine

2,2-dimethoxy-propane
77-76-9

2,2-dimethoxy-propane

((3aR,4R,6R,6aR)-6-(6-amino-2-chloro-9H-purin-9-yl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methanol
24639-06-3

((3aR,4R,6R,6aR)-6-(6-amino-2-chloro-9H-purin-9-yl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methanol

Conditions
ConditionsYield
With toluene-4-sulfonic acid at 20℃; Cycloaddition;100%
With perchloric acid In water at 20℃; for 8h; Reagent/catalyst; Inert atmosphere;88%
With toluene-4-sulfonic acid In acetone at 45℃;85%
chlorodiethylisopropylsilane
107149-56-4

chlorodiethylisopropylsilane

2-Chloroadenosine
146-77-0

2-Chloroadenosine

2-chloro-2',3',5'-tri-O-(isopropyldiethylsilyl)adenosine
849115-69-1

2-chloro-2',3',5'-tri-O-(isopropyldiethylsilyl)adenosine

Conditions
ConditionsYield
With 1H-imidazole In tetrahydrofuran; DMF (N,N-dimethyl-formamide) at 20℃; for 18h;100%
2-Chloroadenosine
146-77-0

2-Chloroadenosine

butan-1-ol
71-36-3

butan-1-ol

2-Thioadenosine
43157-50-2

2-Thioadenosine

Conditions
ConditionsYield
With hydrogen sulfide; acetic acid In N-methyl-acetamide; water100%
2-Chloroadenosine
146-77-0

2-Chloroadenosine

2-chloro-9-(β-D-arabinofuranosyl)adenine
10147-12-3

2-chloro-9-(β-D-arabinofuranosyl)adenine

Conditions
ConditionsYield
With uridine phosphorylase; disodium hydrogen arsenate heptahydrate; Escherichia coli purine nucleoside phosphorylase for 48h; Enzymatic reaction;99%
2-Chloroadenosine
146-77-0

2-Chloroadenosine

2-hydrazinoadenosine
15763-11-8

2-hydrazinoadenosine

Conditions
ConditionsYield
With hydrazine hydrate at 20℃; for 4h;97%
With hydrazine hydrate In water at 45 - 50℃; Temperature;87%
With hydrazine at 40 - 55℃; for 2h; Product distribution / selectivity;81.4%
2-Chloroadenosine
146-77-0

2-Chloroadenosine

trimethyl orthoformate
149-73-5

trimethyl orthoformate

2-chloro-2′,3′-O-methoxymethylideneadenosine
478702-41-9

2-chloro-2′,3′-O-methoxymethylideneadenosine

Conditions
ConditionsYield
Stage #1: 2-Chloroadenosine; trimethyl orthoformate With toluene-4-sulfonic acid at 20℃;
Stage #2: at 20℃; for 3h;
96%
With toluene-4-sulfonic acid In N,N-dimethyl-formamide at 20℃; for 24h;81%
With toluene-4-sulfonic acid at 20℃;
acetic anhydride
108-24-7

acetic anhydride

2-Chloroadenosine
146-77-0

2-Chloroadenosine

2',3',5'-tri-O-acetyl-2-chloroadenosine
79999-39-6, 24638-99-1

2',3',5'-tri-O-acetyl-2-chloroadenosine

Conditions
ConditionsYield
With dmap; triethylamine In acetonitrile at 50℃;94%
N-BOC-1,2-diaminoethane
57260-73-8

N-BOC-1,2-diaminoethane

2-Chloroadenosine
146-77-0

2-Chloroadenosine

tert-butyl (2-((6-amino-9-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-9H-purin-2-yl)amino)ethyl)carbamate
847647-31-8

tert-butyl (2-((6-amino-9-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-9H-purin-2-yl)amino)ethyl)carbamate

Conditions
ConditionsYield
at 150℃; for 2h; Inert atmosphere; Neat (no solvent);91.4%
2-Chloroadenosine
146-77-0

2-Chloroadenosine

acetone
67-64-1

acetone

((3aR,4R,6R,6aR)-6-(6-amino-2-chloro-9H-purin-9-yl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methanol
24639-06-3

((3aR,4R,6R,6aR)-6-(6-amino-2-chloro-9H-purin-9-yl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methanol

Conditions
ConditionsYield
With toluene-4-sulfonic acid at 20℃; Inert atmosphere;90%
With toluene-4-sulfonic acid at 20℃; for 22h; Cooling with ice; Inert atmosphere;83%
With toluene-4-sulfonic acid at 20℃; for 22h; Cooling with ice;83%
2-Chloroadenosine
146-77-0

2-Chloroadenosine

mercaptoacetic acid
68-11-1

mercaptoacetic acid

2-(6-amino-9-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-9H-purin-2-ylthio)acetic acid
58097-84-0

2-(6-amino-9-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-9H-purin-2-ylthio)acetic acid

Conditions
ConditionsYield
In N,N-dimethyl-formamide90%
2-Chloroadenosine
146-77-0

2-Chloroadenosine

toluene-4-sulfonic acid
104-15-4

toluene-4-sulfonic acid

((3aR,4R,6R,6aR)-6-(6-amino-2-chloro-9H-purin-9-yl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methanol
24639-06-3

((3aR,4R,6R,6aR)-6-(6-amino-2-chloro-9H-purin-9-yl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methanol

Conditions
ConditionsYield
In acetone at 20℃; for 4h; Inert atmosphere;90%
2-adamantanethiol
23695-66-1

2-adamantanethiol

2-Chloroadenosine
146-77-0

2-Chloroadenosine

2-(β-adamantyl)thioadenosine

2-(β-adamantyl)thioadenosine

Conditions
ConditionsYield
In N,N-dimethyl-formamide85%
3,3,3-trifluoro-propane-1-thiol
69412-76-6

3,3,3-trifluoro-propane-1-thiol

2-Chloroadenosine
146-77-0

2-Chloroadenosine

2-[(3,3,3-trifluoropropyl)thio]adenosine
163706-51-2

2-[(3,3,3-trifluoropropyl)thio]adenosine

Conditions
ConditionsYield
With potassium carbonate In N,N-dimethyl-formamide for 5h; Reagent/catalyst; Solvent; Reflux;85%
2-Chloroadenosine
146-77-0

2-Chloroadenosine

1-t-Butoxycarbonylpiperazine
57260-71-6

1-t-Butoxycarbonylpiperazine

C19H29N7O6

C19H29N7O6

Conditions
ConditionsYield
With triethylamine In ethanol; water85%
2-Mercaptopyridine
2637-34-5

2-Mercaptopyridine

2-Chloroadenosine
146-77-0

2-Chloroadenosine

2-(β-pyridyl)thioadenosine

2-(β-pyridyl)thioadenosine

Conditions
ConditionsYield
In N,N-dimethyl-formamide80%
p-Aminophenethylamine
13472-00-9

p-Aminophenethylamine

2-Chloroadenosine
146-77-0

2-Chloroadenosine

2-[2-(4-aminophenyl)ethylamino]adenosine
161536-30-7

2-[2-(4-aminophenyl)ethylamino]adenosine

Conditions
ConditionsYield
With N-ethyl-N,N-diisopropylamine at 140℃; for 4h; Substitution;79%
2-Chloroadenosine
146-77-0

2-Chloroadenosine

carbonic acid dimethyl ester
616-38-6

carbonic acid dimethyl ester

2-(methylthio)adenosine
4105-39-9

2-(methylthio)adenosine

Conditions
ConditionsYield
With potassium tert-butylate; palladium diacetate; triphenylphosphine; potassium thioacetate In dimethyl sulfoxide at 120℃; Inert atmosphere;77%
2-Chloroadenosine
146-77-0

2-Chloroadenosine

(2R,3R,4S,5S)-2-(6-amino-2-chloro-9H-purin-9-yl)-5-(chloromethyl)tetrahydrofuran-3,4-diol, also called 5'-deoxy-5'-(chloro)-2-chloroadenosine

(2R,3R,4S,5S)-2-(6-amino-2-chloro-9H-purin-9-yl)-5-(chloromethyl)tetrahydrofuran-3,4-diol, also called 5'-deoxy-5'-(chloro)-2-chloroadenosine

Conditions
ConditionsYield
With N,N,N,N,N,N-hexamethylphosphoric triamide; thionyl chloride at 20℃; Inert atmosphere;76%
2-Chloroadenosine
146-77-0

2-Chloroadenosine

methylamine
74-89-5

methylamine

2-(methylamino)adenosine
13364-95-9

2-(methylamino)adenosine

Conditions
ConditionsYield
In ethanol; water at 100℃; for 132h; Sealed tube;75%
1,3-Dichloro-1,1,3,3-tetraisopropyldisiloxane
69304-37-6

1,3-Dichloro-1,1,3,3-tetraisopropyldisiloxane

2-Chloroadenosine
146-77-0

2-Chloroadenosine

(6aR,8R,9R,9aS)-8-(6-amino-2-chloro-9H-purin-9-yl)-2,2,4,4-tetraisopropyltetrahydro-6H-furo[3,2-f][1,3,5,2,4]trioxadisilocin-9-ol
111556-90-2

(6aR,8R,9R,9aS)-8-(6-amino-2-chloro-9H-purin-9-yl)-2,2,4,4-tetraisopropyltetrahydro-6H-furo[3,2-f][1,3,5,2,4]trioxadisilocin-9-ol

Conditions
ConditionsYield
With 1H-imidazole In tetrahydrofuran; DMF (N,N-dimethyl-formamide) at 20℃; for 24h;72%
With pyridine for 1h; Ambient temperature;69%
In pyridine at 20℃;
2-Chloroadenosine
146-77-0

2-Chloroadenosine

2-hydroxyethanethiol
60-24-2

2-hydroxyethanethiol

S-(2-hydroxy-ethyl)-2-thio-isoguanosine
56720-63-9

S-(2-hydroxy-ethyl)-2-thio-isoguanosine

Conditions
ConditionsYield
In N,N-dimethyl-formamide72%
2-(aminoethyl)pyridine
2706-56-1

2-(aminoethyl)pyridine

2-Chloroadenosine
146-77-0

2-Chloroadenosine

2-[2-(pyridin-2-yl)ethylamino]-adenosine
124498-70-0

2-[2-(pyridin-2-yl)ethylamino]-adenosine

Conditions
ConditionsYield
at 140℃; for 4h;71%
2-cyclohexylethylamine
4442-85-7

2-cyclohexylethylamine

2-Chloroadenosine
146-77-0

2-Chloroadenosine

2-[(2-Cyclohexylethyl)amino]adenosine
124498-52-8

2-[(2-Cyclohexylethyl)amino]adenosine

Conditions
ConditionsYield
at 140℃; for 4h;71%
isopropyldimethylsilyl chloride
3634-56-8

isopropyldimethylsilyl chloride

2-Chloroadenosine
146-77-0

2-Chloroadenosine

2-chloro-2',3',5'-tri-O-(isopropyldimethylsilyl)adenosine
849115-65-7

2-chloro-2',3',5'-tri-O-(isopropyldimethylsilyl)adenosine

Conditions
ConditionsYield
With 1H-imidazole In tetrahydrofuran; DMF (N,N-dimethyl-formamide) at 20℃; for 18h;70%
4,4'-dimethoxytrityl chloride
40615-36-9

4,4'-dimethoxytrityl chloride

2-Chloroadenosine
146-77-0

2-Chloroadenosine

2-Chloro-5'-O-(4,4'-dimethoxytrityl)adenosine
119530-57-3

2-Chloro-5'-O-(4,4'-dimethoxytrityl)adenosine

Conditions
ConditionsYield
With pyridine for 24h; Ambient temperature;69%

146-77-0Relevant articles and documents

Structure-Guided Tuning of a Selectivity Switch towards Ribonucleosides in Trypanosoma brucei Purine Nucleoside 2′-Deoxyribosyltransferase

Del Arco, Jon,Mills, Alberto,Gago, Federico,Fernández-Lucas, Jesús

, p. 2996 - 3000 (2019)

The use of nucleoside 2′-deoxyribosyltransferases (NDTs) as biocatalysts for the industrial synthesis of nucleoside analogues is often hindered by their strict preference for 2′-deoxyribonucleosides. It is shown herein that a highly versatile purine NDT from Trypanosoma brucei (TbPDT) can also accept ribonucleosides as substrates; this is most likely because of the distinct role played by Asn53 at a position that is usually occupied by Asp in other NDTs. Moreover, this unusual activity was improved about threefold by introducing a single amino acid replacement at position 5, following a structure-guided approach. Biophysical and biochemical characterization revealed that the TbPDTY5F variant is a homodimer that displays maximum activity at 50 °C and pH 6.5 and shows a remarkably high melting temperature of 69 °C. Substrate specificity studies demonstrate that 6-oxopurine ribonucleosides are the best donors (inosine>guanosine?adenosine), whereas no significant preferences exist between 6-aminopurines and 6-oxopurines as base acceptors. In contrast, no transferase activity could be detected on xanthine and 7-deazapurines. TbPDTY5F was successfully employed in the synthesis of a wide range of modified ribonucleosides containing different purine analogues.

Protonation studies of modified adenine and adenine nucleotides by theoretical calculations and 15N NMR

Major, Dan T.,Laxer, Avital,Fischer, Bilha

, p. 790 - 802 (2002)

The acid/base character of nucleobases affects phenomena such as self-association, interaction with metal ions, molecular recognition by proteins, and nucleic acid base-pairing. Therefore, the investigation of proton-transfer equilibria of natural and synthetic nucleos(t)ides is of great importance to obtain a deeper understanding of these phenomena. For this purpose, a set of ATP prototypes was investigated using 15N NMR spectroscopy, and the corresponding adenine bases were investigated by theoretical calculations. 15N NMR measurements provided not only acidity constants but also information on the protonation site(s) on the adenine ring and regarding the ratio of the singly protonated species in equilibrium. Substituents of different nature and position on the adenine ring did not change the preferred protonation site, which remained N1. However, for 2-thioether-ATP derivatives a mixed population of N1 and N7 singly protonated species was observed. Reduction of basicity of 0.4-1 pKa units relative to ATP was also observed for all evaluated ATP derivatives, except for 2-Cl-ATP, for which Ka was ca. 10,000-fold lower. To explain the substitution-dependent variations in the experimental pKa values of the ATP analogues, gas-phase proton affinities (PA), ΔΔGhyd, and pKa values of the corresponding adenine bases were calculated using quantum mechanical methods. The computed PA and ΔΔGhyd values successfully explained the experimental pKa values. A computational procedure for the prediction of accurate pKa values was developed using density functional theory and polarizable continuum model calculations. In this procedure, we developed a set of parameters for the polarizable continuum model that was fitted to reproduce experimental pKa values of nitrogen heterocycles. This method is proposed for the prediction of pKa values and protonation site(s) of purine analogues that have not been synthesized or analyzed.

Thermodynamic Reaction Control of Nucleoside Phosphorolysis

Kaspar, Felix,Giessmann, Robert T.,Neubauer, Peter,Wagner, Anke,Gimpel, Matthias

, p. 867 - 876 (2020/01/24)

Nucleoside analogs represent a class of important drugs for cancer and antiviral treatments. Nucleoside phosphorylases (NPases) catalyze the phosphorolysis of nucleosides and are widely employed for the synthesis of pentose-1-phosphates and nucleoside analogs, which are difficult to access via conventional synthetic methods. However, for the vast majority of nucleosides, it has been observed that either no or incomplete conversion of the starting materials is achieved in NPase-catalyzed reactions. For some substrates, it has been shown that these reactions are reversible equilibrium reactions that adhere to the law of mass action. In this contribution, we broadly demonstrate that nucleoside phosphorolysis is a thermodynamically controlled endothermic reaction that proceeds to a reaction equilibrium dictated by the substrate-specific equilibrium constant of phosphorolysis, irrespective of the type or amount of NPase used, as shown by several examples. Furthermore, we explored the temperature-dependency of nucleoside phosphorolysis equilibrium states and provide the apparent transformed reaction enthalpy and apparent transformed reaction entropy for 24 nucleosides, confirming that these conversions are thermodynamically controlled endothermic reactions. This data allows calculation of the Gibbs free energy and, consequently, the equilibrium constant of phosphorolysis at any given reaction temperature. Overall, our investigations revealed that pyrimidine nucleosides are generally more susceptible to phosphorolysis than purine nucleosides. The data disclosed in this work allow the accurate prediction of phosphorolysis or transglycosylation yields for a range of pyrimidine and purine nucleosides and thus serve to empower further research in the field of nucleoside biocatalysis. (Figure presented.).

2-Substituted α,β-Methylene-ADP Derivatives: Potent Competitive Ecto-5′-nucleotidase (CD73) Inhibitors with Variable Binding Modes

Bhattarai, Sanjay,Pippel, Jan,Scaletti, Emma,Idris, Riham,Freundlieb, Marianne,Rolshoven, Georg,Renn, Christian,Lee, Sang-Yong,Abdelrahman, Aliaa,Zimmermann, Herbert,El-Tayeb, Ali,Müller, Christa E.,Str?ter, Norbert

, p. 2941 - 2957 (2020/04/10)

CD73 inhibitors are promising drugs for the (immuno)therapy of cancer. Here, we present the synthesis, structure-activity relationships, and cocrystal structures of novel derivatives of the competitive CD73 inhibitor α,β-methylene-ADP (AOPCP) substituted in the 2-position. Small polar or lipophilic residues increased potency, 2-iodo- and 2-chloro-adenosine-5′-O-[(phosphonomethyl)phosphonic acid] (15, 16) being the most potent inhibitors with Ki values toward human CD73 of 3-6 nM. Subject to the size and nature of the 2-substituent, variable binding modes were observed by X-ray crystallography. Depending on the binding mode, large species differences were found, e.g., 2-piperazinyl-AOPCP (21) was >12-fold less potent against rat CD73 compared to human CD73. This study shows that high CD73 inhibitory potency can be achieved by simply introducing a small substituent into the 2-position of AOPCP without the necessity of additional bulky N6-substituents. Moreover, it provides valuable insights into the binding modes of competitive CD73 inhibitors, representing an excellent basis for drug development.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 146-77-0